NDAORALSOLUTION
Approved
Jan 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
BRYNOVIN (sitagliptin hydrochloride oral) by R-Pharm US is dipeptidyl peptidase 4 inhibitors [moa]. Approved for type 2 diabetes mellitus. First approved in 2025.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRYNOVIN is a DPP-4 inhibitor oral solution containing sitagliptin hydrochloride, approved January 2025 for type 2 diabetes mellitus. It works by inhibiting dipeptidyl peptidase-4, an enzyme that degrades incretin hormones, thereby enhancing glucose-dependent insulin secretion and improving glycemic control. This represents a newer oral formulation in the established DPP-4 class.
Growth14.0 years to LOE
Early-stage growth product with 14 years of patent protection; small team likely focused on market penetration and formulary access in competitive DPP-4 space.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications (1)
Career Relevance
BRYNOVIN presents a stable, early-growth career opportunity in a mature therapeutic area with established commercial infrastructure but intensifying competitive pressure from newer mechanism classes. Positions suit professionals focused on formulary management, payer strategy, and defensive market positioning rather than transformative innovation.
Worked on BRYNOVIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.